FranΓ§aisπ See the interactive version (live chart) β
| Metric | Value | What it means |
|---|---|---|
| P/E (price / earnings) | 37.4 | The higher, the more growth the market expects. |
| Forward P/E | 9.7 | On next year's expected earnings. Lower than current P/E = rising earnings. |
| PEG (P/E Γ· growth) | β | Below 1 = cheap given growth; above 2 = expensive. |
| Net margin | 7% | Share of revenue that ends up as profit. |
| Revenue growth | 3% | Pace of revenue growth. |
| Price-to-book | 1.9 | Price relative to book value. |
| Market cap | $159.7 B | Total market value of the company. |
| Dividend yield | 7.20% | Annual dividend ~$1.72/share relative to price. |
| Year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2022 | $100.3 B | $31.4 B | 31% |
| 2023 | $58.5 B | $2.1 B | 4% |
| 2024 | $63.6 B | $8.0 B | 13% |
| 2025 | $62.6 B | $7.8 B | 12% |
π Open the interactive Pfizer page (charts, live news) β
Pfizer has a P/E of 37.4 (forward P/E 9.7) and a PEG of β. A PEG below 1 is rather cheap given growth, above 2 is expensive. Verdict: valuation to review.
Pfizer's net margin is about 7% β the share of revenue that ends up as net profit.
Latest known revenue: $62.6 B for net income of $7.8 B. The year-by-year breakdown is in the income statement above.
Pfizer (PFE) has a market cap of about $159.7 B.
Yes: Pfizer pays about $1.72/share per year, i.e. roughly a 7.20% yield at the current price.
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best β on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
Explore JPI Invest for free β How it works: the method β
β οΈ Educational information, not investment advice. Data: Yahoo Finance, recomputed by JPI Invest. A stock can be Β« cheap Β» for a bad reason.